Critical Comparison: Rallybio (RLYB) and Its Peers

Rallybio (NASDAQ:RLYB) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Rallybio to similar businesses based on the strength of its earnings, risk, analyst recommendations, institutional ownership, valuation, profitability and dividends.

Risk and Volatility

Rallybio has a beta of -0.73, suggesting that its stock price is 173% less volatile than the S&P 500. Comparatively, Rallybio’s competitors have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Valuation & Earnings

This table compares Rallybio and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Rallybio	$860,000.00	-$8.98 million	-4.26
Rallybio Competitors	$702.30 million	$9.48 million	-18.96

Rallybio’s competitors have higher revenue and earnings than Rallybio. Rallybio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Rallybio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-31.44%	-29.89%
Rallybio Competitors	-12,323.33%	-195.91%	-30.60%

Institutional and Insider Ownership

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 10.3% of Rallybio shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Rallybio and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1	0	0	0	1.00
Rallybio Competitors	9873	15287	45633	1598	2.54

As a group, “Biotechnology” companies have a potential upside of 125.16%. Given Rallybio’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Rallybio has less favorable growth aspects than its competitors.

Summary

Rallybio competitors beat Rallybio on 7 of the 13 factors compared.

Rallybio Company Profile

Rallybio Corporation is a clinical-stage biotechnology company focused on developing medicines for patients with rare diseases, with an emphasis on conditions that affect maternal and fetal health, as well as other serious disorders with limited treatment options. The company is headquartered in New Haven, Connecticut, and its programs are intended for specialized patient populations in the United States and international markets. Rallybio’s lead program, RLYB212, is being developed to prevent fetal and neonatal alloimmune thrombocytopenia, a rare condition in which maternal antibodies attack fetal platelets during pregnancy.